TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02835703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair of coarctation of aorta
Description: Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair of coarctation of aorta
Description: Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair of coarctation of aorta
Description: Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
Study: NCT01238913

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Endoscopic placement of an esophageal metal stent as per medical indication.
Study: NCT04099706

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Autologous Fat Grafting / Fat Transplant
Description: See arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting / Fat Transplant
Description: See arm descriptions.
Study: NCT04343573

Intervention type: OTHER
Group type: OTHER
Intervention: MDASI-BT and MDASI-SP
Description: Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDASI-BT and MDASI-SP
Description: Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
Study: NCT00295789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: Paclitaxel/Cisplatin
Description: Drug: chemotherapy: Paclitaxel/Cisplatin
Study: NCT01842646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
Study: NCT03276572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: 225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
Study: NCT03667508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expanding Device
Description: The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slow Maxillary Expanding Device
Description: The expansion screw will be activated every five days until correcting the crossbite.
Study: NCT00295789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: Paclitaxel/Carboplatin
Description: Drug: chemotherapy: Paclitaxel/Carboplatin
Study: NCT04454060

Intervention type: PROCEDURE
Intervention: Extracapsular arthroscopy
Description: Extracapsular arthroscopy method was used to treat refractory tennis elbow
Study: NCT02990715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: 1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Scan System
Description: 1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure
Study: NCT01603225

Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
Study: NCT02243683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-024.HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-024.HCl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04486547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information-Motivation-Behavioral Skills model-based intervention
Description: Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
Study: NCT01904929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk-tests
Description: Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2.
Study: NCT00572104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: 12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercise
Description: 12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
Study: NCT01896830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Toxoid Vaccine
Description: 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.5 mL, intramuscular
Study: NCT04691037

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
Study: NCT03079531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg administered subcutaneously.
Study: NCT04232982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).
Description: Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)
Description: Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas.
Study: NCT01266330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dairy
Description: Less than 0.5 standard servings of dairy products per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adequate Dairy
Description: 3.5 standard servings of dairy foods per day
Study: NCT02060786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic clopidogrel (Plavitor® )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: original clopidogrel (Plavix® )
Study: NCT04587882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will get usual care and wear a smartwatch.
Study: NCT04554732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keratinocyte growth factor
Description: At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
Study: NCT01599598

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coherence Advantage
Description: Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
Study: NCT03440801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy
Description: Biodegradable-polymer everolimus-eluting stent Synergy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy
Description: Biodegradable-polymer everolimus-eluting stent Synergy
Study: NCT01562145

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Four mL venous blood samples were collected from all study participants after inclusion

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Four mL venous blood samples were collected from all study participants after inclusion
Study: NCT01902537

Intervention type: DRUG
Intervention: Prucalopride; observational study
Description: This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
Study: NCT03440801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience
Description: Durable-polymer everolimus-eluting stent Xience

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Description: Durable-polymer everolimus-eluting stent Xience
Study: NCT01704508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Study: NCT00326001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gold tip catheter
Description: Radiofrquency ablation using gold tip catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-iridium tip catheter
Description: Radiofrequency ablation using platinum-iridium tip catheter
Study: NCT03826459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Locking Uterine Closure
Description: The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locked Uterine Closure
Description: The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
Study: NCT01504893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protective one lung ventilation
Description: Low tidal volume, PEEP and alveolar recruitment maneuver
Study: NCT03751826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentivised network delivery of HIV-ST
Description: Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer navigator delivery of HIV-ST
Description: Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
Study: NCT04692012

Intervention type: OTHER
Group type: OTHER
Intervention: FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION
Description: VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
Study: NCT02931838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Study: NCT03525457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Non Surgical Periodontal Therapy in 2 to 3 sessions
Study: NCT05671315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue
Description: 1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue
Description: NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse.
Study: NCT01001728

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Imaging investigations (with radiation)
Study: NCT02931838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986165
Study: NCT01526941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
Study: NCT01027650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: Dexamethasone 700 ug intravitreal implant on Day 1.
Study: NCT03281629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS stimulation
Description: Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS stimulation
Description: Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
Study: NCT03549338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futuximab
Description: Futuximab is one of two mAb components that constitute Sym004.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modotuximab
Description: Modotuximab is one of two mAb components that constitute Sym004.